Company profile
Home - Stablepharma
StablevaX is a disruptive technology platform that aims to produce fridge-free vaccines to eliminate the need for the global cold chain
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
CH01 | Transaction MzQ0NDEzNzI1MWFkaXF6a2N4
Published 19 Nov 2024 04:49
AP01 | Transaction MzQ0MjYzNjk4M2FkaXF6a2N4
Published 11 Nov 2024 12:17
SH01 | Transaction MzQzOTAwODA1NWFkaXF6a2N4
Published 10 Oct 2024 05:10
AA | Transaction MzQzNzE3NTIxMWFkaXF6a2N4 | Paper/PDF filed
Published 01 Oct 2024 06:17
SH01 | Transaction MzQzMzYzODg1NmFkaXF6a2N4
Published 28 Aug 2024 12:38
SH01 | Transaction MzQzMzYzODUzN2FkaXF6a2N4
Published 28 Aug 2024 12:35
SH01 | Transaction MzQzMzYzODI2OWFkaXF6a2N4
Published 28 Aug 2024 12:33
Company registered at Companies House
1 Dec 2023 to 31 May 2025
Vaccines save ~3 million lives globally each year by preventing many infectious, serious, and potentially deadly diseases including smallpox, polio, measles and diphtheria). Vaccines are normally supplied in liquid form which requires constant refrigeration between 2 to 8°C. According to UNICEF, delivering vaccines using a temperature controlled supply ch...
1 Nov 2020 to 30 Apr 2022
Vaccines save ~3million lives globally by preventing many infectious, serious and potentially deadly diseases (smallpox/polio/measles/diphtheria) by ~99.9%\[NHS,2019\]. Vaccines are normally supplied in liquid form which requires constant refrigeration between 2-8 degC. Global cost of delivering this cold-chain is £328million/annum. Repeated episodes of t...
